Press Release: Eterna Therapeutics Completes Strategic Financial Restructuring With the Aim to Accelerate Its Developmental Activities and Long-Term Success

Dow Jones10/30 20:30

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

GlobeNewswire10/17 20:00

エテルナ セラピューティクス | 10-Q：Q2 2024 四半期報告書

SEC08/14 04:36

12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga06/04 00:31

10-Q：Q1 2024 四半期報告書

SEC05/15 05:20

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) IMSC Line With Enhanced Immunosuppressive Activity and Stealthing Features That May Further Augment the Therapeutic Potential of...

GlobeNewswire05/10 20:00